Tudor Investment Corp ET AL Decreases Stake in Xeris Biopharma Holdings, Inc. $XERS

Tudor Investment Corp ET AL lessened its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 83.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 37,994 shares of the company’s stock after selling 187,192 shares during the period. Tudor Investment Corp ET AL’s holdings in Xeris Biopharma were worth $309,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Calamos Advisors LLC acquired a new stake in shares of Xeris Biopharma in the 3rd quarter worth approximately $1,116,000. Voya Investment Management LLC increased its position in shares of Xeris Biopharma by 866.6% in the third quarter. Voya Investment Management LLC now owns 400,079 shares of the company’s stock valued at $3,257,000 after buying an additional 358,689 shares in the last quarter. Divisadero Street Capital Management LP purchased a new position in shares of Xeris Biopharma in the third quarter valued at $3,308,000. Squarepoint Ops LLC raised its stake in shares of Xeris Biopharma by 1,679.1% during the 2nd quarter. Squarepoint Ops LLC now owns 284,567 shares of the company’s stock worth $1,329,000 after buying an additional 268,572 shares during the last quarter. Finally, Granahan Investment Management LLC acquired a new stake in Xeris Biopharma in the 3rd quarter valued at about $2,850,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Price Performance

NASDAQ:XERS opened at $6.04 on Thursday. Xeris Biopharma Holdings, Inc. has a 12-month low of $3.81 and a 12-month high of $10.08. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -603.40 and a beta of 0.61. The company’s 50-day moving average is $6.39 and its two-hundred day moving average is $7.31. The company has a current ratio of 2.19, a quick ratio of 1.57 and a debt-to-equity ratio of 16.10.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Monday, March 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03. The business had revenue of $85.81 million for the quarter, compared to the consensus estimate of $86.00 million. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. Research analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Insider Transactions at Xeris Biopharma

In related news, insider John Patrick Shannon, Jr. sold 24,907 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $7.08, for a total value of $176,341.56. Following the sale, the insider directly owned 2,705,346 shares of the company’s stock, valued at approximately $19,153,849.68. This trade represents a 0.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Beth Hecht sold 16,667 shares of Xeris Biopharma stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $7.43, for a total value of $123,835.81. Following the completion of the transaction, the insider owned 1,308,103 shares in the company, valued at $9,719,205.29. The trade was a 1.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 89,908 shares of company stock worth $648,515 in the last three months. Company insiders own 6.47% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on XERS shares. Barclays began coverage on shares of Xeris Biopharma in a research report on Monday, December 8th. They set an “overweight” rating and a $9.00 target price for the company. Weiss Ratings upgraded shares of Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, March 4th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a research note on Monday, March 2nd. Finally, Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Xeris Biopharma currently has a consensus rating of “Moderate Buy” and an average target price of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.